IDEAYA Biosciences, Inc. $IDYA Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd reduced its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 32.6% in the 1st quarter, HoldingsChannel.com reports. The firm owned 54,618 shares of the company’s stock after selling 26,415 shares during the period. Y Intercept Hong Kong Ltd’s holdings in IDEAYA Biosciences were worth $1,820,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its position in IDEAYA Biosciences by 171.1% during the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after purchasing an additional 580 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its position in shares of IDEAYA Biosciences by 49.4% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after buying an additional 380 shares in the last quarter. Global Retirement Partners LLC purchased a new position in shares of IDEAYA Biosciences in the fourth quarter valued at $61,000. Daiwa Securities Group Inc. raised its stake in shares of IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after buying an additional 436 shares during the last quarter. Finally, Comerica Bank raised its stake in shares of IDEAYA Biosciences by 36.5% during the 4th quarter. Comerica Bank now owns 2,514 shares of the company’s stock worth $87,000 after buying an additional 672 shares during the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Stock Down 1.8%

Shares of NASDAQ:IDYA opened at $37.28 on Friday. IDEAYA Biosciences, Inc. has a 52-week low of $21.33 and a 52-week high of $40.58. The stock’s fifty day simple moving average is $31.32 and its 200-day simple moving average is $32.60. The company has a market capitalization of $3.28 billion, a P/E ratio of -23.30 and a beta of -0.09.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The company had revenue of $6.56 million during the quarter, compared to analyst estimates of $5.04 million. The firm’s revenue was down 39.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.82) earnings per share. On average, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -4.1 earnings per share for the current year.

Analyst Ratings Changes

IDYA has been the topic of several recent research reports. Citigroup reiterated a “market outperform” rating on shares of IDEAYA Biosciences in a research report on Tuesday, June 2nd. Wedbush restated an “outperform” rating and set a $58.00 target price on shares of IDEAYA Biosciences in a research report on Friday, June 12th. Truist Financial reduced their price target on shares of IDEAYA Biosciences from $65.00 to $63.00 and set a “buy” rating on the stock in a report on Tuesday. Royal Bank Of Canada lowered their price target on shares of IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Guggenheim raised their price objective on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. Fifteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.25.

Insider Transactions at IDEAYA Biosciences

In other IDEAYA Biosciences news, CAO Briseno Andres Ruiz sold 9,550 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total value of $382,095.50. Following the transaction, the chief accounting officer directly owned 26,466 shares in the company, valued at approximately $1,058,904.66. This represents a 26.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.